3-{2-[2-(2-methoxyethoxy)ethoxy]ethoxy}propylamine | 71794-29-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-{2-[2-(2-methoxyethoxy)ethoxy]ethoxy}propylamine
• 英文别名: 2,5,8,11-Tetraoxatetradecan-14-amine；3-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]propan-1-amine
• CAS: 71794-29-1
• 化学式: C₁₀H₂₃NO₄
• 分子量: 221.297
• InChiKey: QMPRGGKWKDAMNZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  15
• 可旋转键数：
  12
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  62.9
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3-{2-[2-(2-methoxyethoxy)ethoxy]ethoxy}propylamine 、 2,6-bis(3-bromopropionamido)anthracene-9,10-dione 以 乙醇 为溶剂， 生成 3-[3-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]propylamino]-N-[6-[3-[3-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]propylamino]propanoylamino]-9,10-dioxoanthracen-2-yl]propanamide
  参考文献：
  名称：

  一系列蒽醌与DNA的结合。

  摘要：

  研究了一系列在其侧链带有一个至四个乙二醇单元的同源2，6-二取代蒽醌穿线嵌入剂的DNA结合特性。结合常数通过表面等离振子共振（SPR）测量。这些化合物以比富含GC的发夹略高的亲和力与富含AT的发夹结合。结合常数随着侧链长度的增加而降低。

  DOI：

  10.1016/j.bmcl.2003.10.054
• 作为产物：
  描述：

  三甘醇单甲醚 在 Rh/Al₂O₃ 氢气 作用下， 生成 3-{2-[2-(2-methoxyethoxy)ethoxy]ethoxy}propylamine
  参考文献：
  名称：

  一系列蒽醌与DNA的结合。

  摘要：

  研究了一系列在其侧链带有一个至四个乙二醇单元的同源2，6-二取代蒽醌穿线嵌入剂的DNA结合特性。结合常数通过表面等离振子共振（SPR）测量。这些化合物以比富含GC的发夹略高的亲和力与富含AT的发夹结合。结合常数随着侧链长度的增加而降低。

  DOI：

  10.1016/j.bmcl.2003.10.054

文献信息

• [EN] BI-FUNCTIONAL MOLECULES TO DEGRADE CIRCULATING PROTEINS<br/>[FR] MOLÉCULES BI-FONCTIONNELLES POUR DÉGRADER DES PROTÉINES CIRCULANTES
  申请人：UNIV YALE

  公开号：WO2019199621A1

  公开（公告）日：2019-10-17

  The present invention is directed to bi-functional compounds which find use as pharmaceutical agents in the treatment of disease states and/or conditions which are through.macrophage migration inhibitory factor (MIF) or immunoglubin G (IgG). The present invention is also directed to pharmaceutical compositions which comprise these bi- functional compounds as well as methods for treating disease states and/or conditions which are mediated through MIF/lgG or where MIF/lgG is a contributing factor to the development and perpetuation of diseases and/or conditions, especially including autoimmune diseases and cancer, among others. The purpose of the present invention is to provide a molecular strategy to lower plasma MIF/lgG level in patients with autoimmune diseases or certain types of cancers. The b.i -functional molecule construct is comprised of a MIF/IgQ-targeting motif, that is derived from small molecule MIF/lgG ligands, and an ASGPr- targeting motif that binds to hepatocyte asialoglycoprotein receptor ASGPr). The compounds selectively bind MIF or IgG in plasma and subsequently engage the endo-lysosomal pathway of hepatocytes through ASGPr. As a consequence, MIF/igG is internalized and degraded by hepatocytes, thus resulting in potential attenuation of corresponding disease symptoms which are modulated through MIF/igG.